Cargando…

Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer

Inter-individual variation in tamoxifen metabolism in breast cancer patients is caused by various genetic and clinical factors. We measured the plasma concentrations of tamoxifen and its metabolites and investigated genetic polymorphisms influencing those concentrations. We measured the concentratio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woo, Hye In, Lee, Se Kyung, Kim, Jiyoung, Kim, Seok Won, Yu, Jonghan, Bae, Soo Youn, Lee, Jeong Eon, Nam, Seok Jin, Lee, Soo-Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725021/ https://www.ncbi.nlm.nih.gov/pubmed/29245979 http://dx.doi.org/10.18632/oncotarget.22220

Ejemplares similares

Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells
por: You, Daeun, et al.
Publicado: (2017)

Fertility Rates in Young Korean Breast Cancer Patients Treated with Gonadotropin-Releasing Hormone and Chemotherapy
por: Kim, Isaac, et al.
Publicado: (2017)

Adjuvant Chemotherapy and Survival of Elderly Korean Patients with Breast Carcinoma
por: Jung, Seung Pil, et al.
Publicado: (2012)

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
por: Jager, Nynke GL, et al.
Publicado: (2013)

Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line
por: Won, Hye Sung, et al.
Publicado: (2016)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
por: Moon, Seo Yun, et al.
Publicado: (2021)

Radiation recall dermatitis induced by tamoxifen during adjuvant breast cancer treatment
por: Rhee, Jiyoung, et al.
Publicado: (2014)

Comparison of the Characteristics of Medullary Breast Carcinoma and Invasive Ductal Carcinoma
por: Park, Inhye, et al.
Publicado: (2013)

Assessment of Breast Cancer Patients' Knowledge and Decisional Conflict Regarding Tamoxifen Use
por: Kim, Se Ik, et al.
Publicado: (2015)

Serum Vitamin Levels and Their Relationships with Other Biomarkers in Korean Breast Cancer Patients
por: Kim, Jee Ah, et al.
Publicado: (2020)

Serum Trace Elements and Their Associations with Breast Cancer Subgroups in Korean Breast Cancer Patients
por: Choi, Rihwa, et al.
Publicado: (2018)

Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
por: Chen, Yuanhuang, et al.
Publicado: (2021)

Conditional disease-free survival among patients with breast cancer
por: Paik, Hyun-June, et al.
Publicado: (2017)

Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer
por: Park, Sungmin, et al.
Publicado: (2017)

Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors
por: Park, Jin Young, et al.
Publicado: (2013)

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
por: MacCallum, J, et al.
Publicado: (2000)

Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study
por: Ryu, Jai Min, et al.
Publicado: (2017)

Tubular Carcinoma of the Breast: Clinicopathologic Features and Survival Outcome Compared with Ductal Carcinoma In Situ
por: Min, Yejin, et al.
Publicado: (2013)

Risk of fatty liver after long-term use of tamoxifen in patients with breast cancer
por: Yoo, Jeong-Ju, et al.
Publicado: (2020)

Validation of a Web-Based Tool to Predict the Ipsilateral Breast Tumor Recurrence (IBTR! 2.0) after Breast-Conserving Therapy for Korean Patients
por: Jung, Seung Pil, et al.
Publicado: (2013)

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients
por: Ximenez, João Paulo Bianchi, et al.
Publicado: (2019)

Erratum: Validation of a Web-Based Tool to Predict the Ipsilateral Breast Tumor Recurrence (IBTR! 2.0) after Breast-Conserving Therapy for Korean Patients
por: Jung, Seung Pil, et al.
Publicado: (2017)

Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
por: Lien, Ernst A., et al.
Publicado: (2013)

GSTM1, GSTT1 and GSTP1 Polymorphisms in the Korean Population
por: Cho, Hyun-Jung, et al.
Publicado: (2005)

Feature of amenorrhea in postoperative tamoxifen users with breast cancer
por: Kim, Hoon, et al.
Publicado: (2017)

IARC on tamoxifen.
Publicado: (1996)

Tamoxifen evolution
por: Howell, A., et al.
Publicado: (2023)

Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer
por: Kim, Jae-Myung, et al.
Publicado: (2018)

Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen
por: Jeon, Se Jeong, et al.
Publicado: (2017)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer
por: Bae, Soo Youn, et al.
Publicado: (2015)

Knockdown of vps54 aggravates tamoxifen-induced cytotoxicity in fission yeast
por: Lee, Sol, et al.
Publicado: (2021)

Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy
por: Park, Jeong Hyun, et al.
Publicado: (2018)

Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its Metabolites
por: Khalaj, Zahra, et al.
Publicado: (2019)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
por: Park, Hyung Seok, et al.
Publicado: (2011)

Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen
por: Baek, Soo Yeon, et al.
Publicado: (2019)

Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival
por: Lee, Se Kyung, et al.
Publicado: (2015)

Acute Pancreatitis Caused by Tamoxifen-Induced Severe Hypertriglyceridemia After 4 Years of Tamoxifen Use
por: Tey, Tze Tong, et al.
Publicado: (2019)

Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients
por: Bang, Yoon Ju, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_18tvr4vp2rf9ku7q56klkug18k